Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-02-28FDA Approved: QUILLICHEW ER — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for QUILLICHEW ER (methylphenidate hydrochloride) by NextWave Pharmaceuticals, Inc., resulting i…
-
CLINICAL_TRIALS trial_result · 2017-02-23Clinical Trial Update: Text Messaging Adherence to Stimulant Medication [NA]
Update on a completed clinical trial evaluating text messaging to support adherence to stimulant medication for Attention Deficit Hyperactiv…
-
CLINICAL_TRIALS trial_result · 2017-02-13Clinical Trial Update: Concerta (Methylphenidate) -To-Generic Switch Study
A completed clinical trial evaluating switching from Concerta to a generic methylphenidate formulation for attention-deficit/hyperactivity d…
-
CLINICAL_TRIALS trial_result · 2017-02-03Clinical Trial Update: Executive Function/Metacognitive Training for At-Risk Preschoolers [NA]
This clinical trial update notes the completion of a study evaluating executive function/metacognitive training for preschoolers at risk for…
-
FDA approval · 2017-02-01FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (KVK-Tech, Inc.)
FDA approved a supplemental application for Dextroamphetamine sulfate from KVK-Tech, Inc., under an ANDA. This action confirms approval of a…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-02-01Clinical Trial Update: Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial [NA]
This clinical trials entry reports a randomized controlled trial examining behavioural sleep interventions for children with ADHD, with curr…
-
CLINICAL_TRIALS withdrawal · 2017-01-31Clinical Trial Update: Executive Functioning and Mindfulness in Adults With Attention Deficit/Hyperactivity Disorder Imaging [NA]
A clinical trial investigating executive functioning and mindfulness in adults with attention-deficit/hyperactivity disorder has been withdr…
-
FDA approval · 2017-01-28FDA Approved: VYVANSE — Original Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved Vyvanse (lisdexamfetamine dimesylate) from Takeda as an original drug application (NDA 208510). It is approved for the trea…
-
FDA approval · 2017-01-24FDA Approved: QUILLIVANT XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
FDA approved a supplemental application for QUILLIVANT XR (methylphenidate hydrochloride) from NextWave Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2017-01-19Clinical Trial Update: A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD [Phase 3]
A Phase 3 trial comparing PRC-063 with lisdexamfetamine to assess driving performance in adults with ADHD has completed.
-
CLINICAL_TRIALS trial_result · 2017-01-19Clinical Trial Update: The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD [Phase 3]
The MEASURE study, a Phase 3 trial evaluating MDX 1400 mg daily versus placebo in adults with ADHD, has been terminated.
-
CLINICAL_TRIALS trial_result · 2017-01-16Clinical Trial Update: Methylphendidate Treatment of Cocaine Dependent Patients With Attention Deficit Hyperactivity Disorder - 3 [Phase 2]
Phase 2 trial update evaluating methylphenidate for cocaine use disorder in patients with ADHD; the study conducted by NIDA is completed.
-
CLINICAL_TRIALS trial_result · 2017-01-16Clinical Trial Update: CBT for Patients With Attention Deficit Hyperactivity Disorder (ADHD) and Substance Use Disorders [NA]
This clinical trial update notes the completion of a study evaluating cognitive-behavioral therapy for patients with ADHD and substance use …
-
CLINICAL_TRIALS research · 2017-01-13Clinical Trial Update: Association Between Smoking, Brain Activity, Genes, and ADHD
A completed clinical trial explores the associations among smoking behavior, brain activity, genetics, and ADHD; results were posted in 2017…
-
CLINICAL_TRIALS trial_result · 2017-01-12Clinical Trial Update: Cocaine Abuse and ADHD - 10 [Phase 2]
Phase 2 trial evaluating treatments for cocaine-related disorders, including comorbid ADHD, has completed.
-
FDA approval · 2017-01-06FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
FDA approved a supplemental application for Vyvanse (lisdexamfetamine dimesylate) submitted by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2017-01-06FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (NorthStar RxLLC)
The FDA approved a supplemental ANDA for a generic combination of amphetamine salts (dextroamphetamine and amphetamine sulfates) from NorthS…
-
FDA approval · 2017-01-06FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application from Prasco Laboratories for a generic combination of four amphetamine salts (dextroamphetamine …
-
FDA label_change · 2017-01-04FDA Approved: QUILLICHEW ER — Supplemental Application (NextWave Pharmaceuticals, Inc)
FDA approved a supplemental application for Quillichew ER (methylphenidate hydrochloride) from NextWave Pharmaceuticals, resulting in update…
-
FDA approval · 2017-01-04FDA Approved: AMPHETAMINE EXTENDED-RELEASE — Supplemental Application (Neos Therapeutics, LP)
FDA approved a supplemental application for Amphetamine Extended-Release by Neos Therapeutics, LP under NDA 204326.
-
FDA approval · 2017-01-04FDA Approved: FOCALIN XR — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for FOCALIN XR (dexmethylphenidate hydrochloride) submitted by Sandoz Inc.
-
FDA approval · 2017-01-04FDA Approved: METHYLPHENIDATE HYDROCHLORIDE CD — Supplemental Application (Lannett Company, Inc.)
FDA approved a supplemental application for methylphenidate hydrochloride CD by Lannett Company, Inc., a controlled-delivery formulation of …
-
FDA approval · 2017-01-04FDA Approved: CONCERTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for CONCERTA (methylphenidate hydrochloride) from Janssen Pharmaceuticals, Inc.
-
FDA approval · 2017-01-04FDA Approved: DEXTROAMPHETAMINE SULFATE — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for dextroamphetamine sulfate from Prasco Laboratories.
-
FDA approval · 2017-01-04FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approves Teva's supplemental application to add dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amph…